Outcome of older (>= 70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study
Por:
Kayser, S, Rahme, R, Martinez-Cuadron, D, Ghiaur, G, Thomas, X, Sobas, M, Guerci-Bresler, A, Garrido, A, Pigneux, A, Gil, C, Raffoux, E, Tormo, M, Vey, N, de la Serna, J, Salamero, O, Lengfelder, E, Levis, M, Fenaux, P, Sanz, M, Platzbecker, U, Schlenk, R, Ades, L and Montesinos, P
Publicada:
1 sep 2020
Ahead of Print:
1 feb 2020
Resumen:
Data on outcome in older (>= 70 years) patients with acute promyelocytic leukemia after treatment with arsenic trioxide (ATO) compared with standard chemotherapy (CTX) is scarce. We evaluated 433 patients (median age, 73.4 years) treated either with ATO+ all-trans retinoic acid (ATO/ATRA; n = 26), CTX/ATRA + ATO during consolidation (CTX/ATRA/ATO; n = 148), or with CTX/ATRA (n = 259). Median follow-up for overall survival (OS) was 4.8 years. Complete remissions (CR) were achieved in 92% with ATO/ATRA and 82% with CTX/ATRA; induction death rates were 8% and 18%, respectively. For analysis of postremission outcomes we combined the ATO/ATRA and CTX/ATRA/ATO groups (ATO/ATRA +/- CTX). Cumulative incidence of relapse (CIR) was significantly lower after ATO/ATRA +/- CTX compared with CTX/ATRA (P < 0.001). The same held true when restricting the analysis according to the treatment period after the year 2000. OS of patients in CR1 was not different between ATO/ATRA +/- CTX compared with CTX/ATRA (P = 0.20). High (>10 x 10(9)/l) white blood cell (WBC) counts at diagnosis were associated with higher CIR (P < 0.001) compared with lower WBC in the CTX/ATRA group, but not in the ATO/ATRA +/- CTX group (P = 0.48). ATO, when added to ATRA or CTX/ATRA is feasible and effective in elderly patients for remission induction and consolidation, particularly in patients with high WBC at diagnosis.
Filiaciones:
Kayser, S:
Univ Hosp Leipzig, Med Clin & Policlin 1, Hematol & Cellular Therapy, Leipzig, Germany
German Canc Res Ctr, Heidelberg, Germany
Heidelberg Univ Hosp, Dept Internal Med 5, Heidelberg, Germany
Rahme, R:
Univ Paris Diderot, Hop St Louis, Paris, France
Martinez-Cuadron, D:
Hosp Univ & Politecn, Hematol Dept, Avinguda Fernando Abril Martorell 106, Valencia 46026, Spain
Inst Carlos III, CIBERONC, Madrid, Spain
Ghiaur, G:
Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
Thomas, X:
Ctr Hosp Lyon Sud, Hosp Civils Lyon, Lyon, France
Sobas, M:
Wroclaw Med Univ, Dept Hematol Blood Neoplasms & Bone Marrow Transp, Wroclaw, Poland
Guerci-Bresler, A:
Nancy Univ Hosp, Dept Hematol, Nancy, France
Garrido, A:
Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Barcelona, Spain
Pigneux, A:
Bordeaux Univ Hosp, Dept Hematol, Bordeaux, France
:
Hosp Gen, Alicante, Spain
Raffoux, E:
Univ Paris Diderot, Hop St Louis, Paris, France
Tormo, M:
Univ Valencia, Hematol Dept, Hosp Clin Univ, INCLIVA Res Inst, Valencia, Spain
Vey, N:
Inst Paoli Calmette, Marseille, France
de la Serna, J:
Hosp 12 Octubre, Madrid, Spain
Salamero, O:
Hosp Univ Vall dHebron, Barcelona, Spain
Lengfelder, E:
Univ Hosp Mannheim, Dept Hematol & Oncol, Mannheim, Germany
Levis, M:
Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
Fenaux, P:
Univ Paris Diderot, Hop St Louis, Paris, France
Sanz, M:
Hosp Univ & Politecn, Hematol Dept, Avinguda Fernando Abril Martorell 106, Valencia 46026, Spain
Inst Carlos III, CIBERONC, Madrid, Spain
Platzbecker, U:
Univ Hosp Leipzig, Med Clin & Policlin 1, Hematol & Cellular Therapy, Leipzig, Germany
Schlenk, R:
Heidelberg Univ Hosp, Dept Internal Med 5, Heidelberg, Germany
German Canc Res Ctr, Natl Ctr Tumor Dis, NCT Trial Ctr, Heidelberg, Germany
Heidelberg Univ Hosp, Heidelberg, Germany
Ades, L:
Univ Paris Diderot, Hop St Louis, Paris, France
Montesinos, P:
Hosp Univ & Politecn, Hematol Dept, Avinguda Fernando Abril Martorell 106, Valencia 46026, Spain
Inst Carlos III, CIBERONC, Madrid, Spain
hybrid, Green Published
|